Core Viewpoint - Fengyuan Pharmaceutical (000153.SZ) released its semi-annual report for 2025, indicating a total institutional holding of 141 million shares, accounting for 30.39% of the company's total equity, with a slight decrease of 0.36 percentage points from the previous quarter [1] Institutional Holdings - As of August 21, 2025, seven institutional investors disclosed their holdings in Fengyuan Pharmaceutical, with a combined shareholding of 141 million shares [1] - The institutional investors include Anhui Wuwei Pharmaceutical Factory, Bengbu Tushan Enterprise Management Co., Ltd., Ma'anshan Fengyuan Enterprise Management Co., Ltd., Anhui Fengyuan Group Co., Ltd., Great Wall Guorong Investment Management Co., Ltd., BARCLAYS BANK PLC, and Guojin 300 Index Enhanced A [1] - The total institutional holding percentage decreased by 0.36 percentage points compared to the previous quarter [1] Public Fund and Foreign Investment - One new public fund disclosed its holdings this period, namely Guojin 300 Index Enhanced A [1] - Two public funds that were previously disclosed did not report this quarter, including Guojin CSI A500 Index Enhanced A and Dongxing Lianzhong One-Year Holding Period Mixed A [1] - One new foreign institution disclosed its holdings, BARCLAYS BANK PLC, while MORGAN STANLEY & CO. INTERNATIONAL PLC was not reported this quarter [1]

Core Viewpoint - Weir Pharmaceuticals (603351.SH) reported its semi-annual results for 2025, highlighting the current institutional investor holdings and changes in share ownership [1] Institutional Holdings - As of August 19, 2025, three institutional investors disclosed holding a total of 18.5823 million shares of Weir Pharmaceuticals, representing 13.72% of the company's total share capital [1] - The institutional holding percentage decreased by 0.66 percentage points compared to the previous quarter [1] Public Fund Holdings - Three public funds were disclosed this period, including Huaxia CSI 500 Index Enhanced A, Dongxing Lianzhong One-Year Holding Period Mixed A, and Dongxing Pharmaceutical Biotechnology Quantitative Stock Selection Mixed A [1] Social Security Fund Holdings - One new social security fund disclosed holding Weir Pharmaceuticals, namely Guotai Fund Management Co., Ltd. - Social Security Fund 2103 Portfolio [1] - One previously undisclosed social security fund, the National Social Security Fund 112 Portfolio, was also noted [1]